Percutaneous Transluminal Angioplasty (PTA) Device

DEVICE3 trials

Sponsors

Abbott Medical Devices, Biotyx Medical (Shenzhen) Co., Ltd., REVA Medical, Inc.

Conditions

Critical Limb IschemiaCritical Limb Ischemia (CLI)

Unknown Phase

LIFE-BTK Randomized Controlled Trial

Active, not recruitingNCT04227899

Abbott Medical DevicesCritical Limb Ischemia (CLI)

Start: 2020-08-18End: 2027-07-31Updated: 2025-12-30

IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease

Biotyx Medical (Shenzhen) Co., Ltd.Critical Limb Ischemia (CLI)

Start: 2021-12-09End: 2024-10-31Target: 120Updated: 2022-03-17

MOTIV BTK Randomized Controlled Trial

Active, not recruitingNCT05406622

REVA Medical, Inc.Critical Limb Ischemia

Start: 2022-06-10End: 2030-03-31Target: 292Updated: 2026-06-18

Related Papers

Long-Term Outcomes of a Drug-Eluting Resorbable Scaffold vs Angioplasty in Infrapopliteal Chronic Limb-Threatening Ischemia: 3-Year Results From the LIFE-BTK Trial.

2026-05-13

Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial

Circulation2025-09-105 citations

Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease

New England Journal of Medicine2023-10-2596 citations